2374 Takeda, S., S. Wegmann, H. Cho, S.L. DeVos, C. Commins, A.D. Roe, S.B. Nicholls, G.A. Carlson, R. Pitstick, C.K. Nobuhara, I. Costantino, M.P. Frosch, D.J. Müller, D. Irimia, and B.T. Hyman. 2015. Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer's disease brain. *Nat. Commun.* 6:8490. doi:10.1038/ncomms9490.

2378 Tcw, J., L. Qian, N.H. Pipalia, M.J. Chao, S.A. Liang, Y. Shi, B.R. Jain, S.E. Bertelsen, M. Kapoor, E. Marcora, E. Sikora, E.J. Andrews, A.C. Martini, C.M. Karch, E. Head, D.M. Holtzman, B. Zhang, M. Wang, F.R. Maxfield, W.W. Poon, and A.M. Goate. 2022. Cholesterol and matrisome pathways dysregulated in astrocytes and microglia. *Cell*. 185:2213-2233.e25. doi:10.1016/j.cell.2022.05.017.

2383 Teng, E., P.T. Manser, K. Pickthorn, F. Brunstein, M. Blendstrup, S. Sanabria Bohorquez, K.R. Wildsmith, B. Toth, M. Dolton, V. Ramakrishnan, A. Bobbala, S.A.M. Sikkes, M. Ward, R.N. Fuji, G.A. Kerchner, and Tauriel Investigators. 2022. Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial. *JAMA Neurol*. 79:758-767. doi:10.1001/jamaneurol.2022.1375.

2388 Tensaouti, Y., T.-S. Yu, and S.G. Kernie. 2020. Apolipoprotein E regulates the maturation of injury-induced adult-born hippocampal neurons following traumatic brain injury. *PloS One*. 2020. 15:e0229240. doi:10.1371/journal.pone.0229240.

2391 Therriault, J., A.L. Benedet, T.A. Pascoal, S. Mathotaarachchi, M. Chamoun, M. Savard, E. Thomas, M.S. Kang, F. Lussier, C. Tissot, M. Parsons, M.N.I. Qureshi, P. Vitali, G. Massarweh, J.-P. Soucy, S. Rej, P. Saha-Chaudhuri, S. Gauthier, and P. Rosa-Neto. 2020. Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β. *JAMA Neurol*. 2020. 77:470-479. doi:10.1001/jamaneurol.2019.4421.

2396 Therriault, J., A.L. Benedet, T.A. Pascoal, S. Mathotaarachchi, M. Savard, M. Chamoun, E. Thomas, M.S. Kang, F. Lussier, C. Tissot, J.-P. Soucy, G. Massarweh, S. Rej, P. Saha-Chaudhuri, J. Poirier, S. Gauthier, P. Rosa-Neto, and Alzheimer's Disease Neuroimaging Initiative. 2021. APOEε4 potentiates the relationship between amyloid-β and tau pathologies. *Mol. Psychiatry*. 2021. 26:5977-5988. doi:10.1038/s41380-020-0688-6.

2401 Thrupp, N., C. Sala Frigerio, L. Wolfs, N.G. Skene, N. Fattorelli, S. Poovathingal, Y. Fourne, P.M. Matthews, T. Theys, R. Mancuso, B. de Strooper, and M. Fiers. 2020. Single-Nucleus RNA-Seq Is Not Suitable for Detection of Microglial Activation Genes in Humans. *Cell Rep*. 2020. 32:108189. doi:10.1016/j.celrep.2020.108189.

2405 Tiraboschi, P., L.A. Hansen, E. Masliah, M. Alford, L.J. Thal, and J. Corey-Bloom. 2004. Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. *Neurology*. 2004. 62:1977-1983. doi:10.1212/01.wnl.0000128091.92139.0f.

2408 Toledo, J.B., H. Zetterberg, A.C. van Harten, L. Glodzik, P. Martinez-Lage, L. Bocchio-Chiavetto, L. Rami, O. Hansson, R. Sperling, S. Engelborghs, R.S. Osorio, H. Vanderstichele, M. Vandijck, H. Hampel, S. Teipl, A. Moghekar, M. Albert, W.T. Hu, J.A. Monge Argilés, A. Gorostidi, C.E. Teunissen, P.P. De Deyn, B.T. Hyman, J.L. Molinuevo, G.B. Frisoni, G. Linazasoro, M.J. de Leon, W.M. van der Flier, P. Scheltens, K. Blennow, L.M. Shaw, J.Q. Trojanowski, and Alzheimer's Disease Neuroimaging Initiative. 2015. Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. *Brain J. Neurol*. 2015. 138:2701-2715. doi:10.1093/brain/awv199.
2416 Tran, K.M., N.E. Kwang, C.A. Butler, A. Gomez-Arboledas, S. Kawauchi, C. Mar, D. Chao, R.A.
2417 Barahona, C. Da Cunha, K.I. Tsourmas, Z. Shi, S. Wang, S. Collins, A. Walker, K.-X. Shi, J.A.
2418 Alcantara, J. Neumann, D.M. Duong, N.T. Seyfried, A.J. Tenner, F.M. LaFerla, L.A. Hohsfield,
2419 V. Swarup, G.R. MacGregor, and K.N. Green. 2025. APOE Christchurch enhances a disease-
2420 associated microglial response to plaque but suppresses response to tau pathology. *Mol.
2421 Neurodegener.* 20:9. doi:10.1186/s13024-024-00793-x.

2422 Trommer, B.L., C. Shah, S.H. Yun, G. Gamkrelidze, E.S. Pasternak, G.L. Ye, M. Sotak, P.M. Sullivan, J.F.
2423 Pasternak, and M.J. LaDu. 2004. ApoE isoform affects LTP in human targeted replacement
2424 mice. *Neuroreport.* 15:2655-2658. doi:10.1097/00001756-200412030-00020.

2425 Tuck, B.J., L.V.C. Miller, T. Katsinelos, A.E. Smith, E.L. Wilson, S. Keeling, S. Cheng, M.J. Vaysburd, C.
2426 Knox, L. Tredgett, E. Metzakopian, L.C. James, and W.A. McEwan. 2022. Cholesterol
2427 determines the cytosolic entry and seeded aggregation of tau. *Cell Rep.* 39:110776.
2428 doi:10.1016/j CELREP. 2022.110776.

2429 Tulloch, J., L. Leong, Z. Thomson, S. Chen, E.-G. Lee, C.D. Keene, S.P. Millard, and C.-E. Yu. 2018. Glia-
2430 specific APOE epigenetic changes in the Alzheimer's disease brain. *Brain Res.* 1698:179-186.
2431 doi:10.1016/j.brainres.2018.08.006.

2432 Tzioras, M., C. Davies, A. Newman, R. Jackson, and T. Spires-Jones. 2019. Invited Review: APOE at the
2433 interface of inflammation, neurodegeneration and pathological protein spread in
2434 Alzheimer's disease. *Neuropathol. Appl. Neurobiol.* 45:327-346. doi:10.1111/nan.12529.

2435 Ulrich, J.D., T.K. Ulland, M. Colonna, and D.M. Holtzman. 2017. Elucidating the Role of TREM2 in
2436 Alzheimer's Disease. *Neuron.* 94:237-248. doi:10.1016/j.neuron.2017.02.042.

2437 Vance, J.E., and H. Hayashi. 2010. Formation and function of apolipoprotein E-containing
2438 lipoproteins in the nervous system. *Biochim. Biophys. Acta.* 1801:806-818.
2439 doi:10.1016/j.bbalip.2010.02.007.

2440 Vance, J.M., L.A. Farrer, Y. Huang, C. Cruchaga, B.T. Hyman, M.A. Pericak-Vance, A.M. Goate, M.D.
2441 Greicius, A.J. Griswold, J.L. Haines, J. Tcw, G.D. Schellenberg, L.-H. Tsai, J. Herz, and D.M.
2442 Holtzman. 2024. Report of the APOE4 National Institute on Aging/Alzheimer Disease
2443 Sequencing Project Consortium Working Group: Reducing APOE4 in Carriers is a Therapeutic
2444 Goal for Alzheimer's Disease. *Ann. Neurol.* 95:625-634. doi:10.1002/ana.26864.

2445 Vautheny, A., C. Duwat, G. Aurégan, C. Joséphine, A.-S. Hérard, C. Jan, J. Mitja, P. Gipchtein, M.-C.
2446 Gaillard, L. Buée, D. Blum, P. Hantraye, G. Bonvento, E. Brouillet, K. Cambon, and A.-P.
2447 Bemelmans. 2021. THY-Tau22 mouse model accumulates more tauopathy at late stage of
2448 the disease in response to microglia deactivation through TREM2 deficiency. *Neurobiol. Dis.*
2449 155:105398. doi:10.1016/j.nbd.2021.105398.

2450 Victor, M.B., N. Leary, X. Luna, H.S. Meharena, A.N. Scannail, P.L. Bozzelli, G. Samaan, M.H. Murdock,
2451 D. von Maydell, A.H. Effenberger, O. Cerit, H.-L. Wen, L. Liu, G. Welch, M. Bonner, and L.-H.
2452 Tsai. 2022. Lipid accumulation induced by APOE4 impairs microglial surveillance of neuronal-
2453 network activity. *Cell Stem Cell.* 29:1197-1212.e8. doi:10.1016/j.stem.2022.07.005.

2454 Vogel, J.W., Y. Iturria-Medina, O.T. Strandberg, R. Smith, E. Levitis, A.C. Evans, O. Hansson,
2455 Alzheimer's Disease Neuroimaging Initiative, and Swedish BioFinder Study. 2020. Spread of
2456 pathological tau proteins through communicating neurons in human Alzheimer's disease.
2457 *Nat. Commun.* 11:2612. doi:10.1038/s41467-020-15701-2.
2458 Vogel, J.W., A.L. Young, N.P. Oxtoby, R. Smith, R. Ossenkoppele, O.T. Strandberg, R. La Joie, L.M.
2459 Aksman, M.J. Grothe, Y. Iturria-Medina, Alzheimer's Disease Neuroimaging Initiative, M.J.
2460 Pontecorvo, M.D. Devous, G.D. Rabinovici, D.C. Alexander, C.H. Lyoo, A.C. Evans, and O.
2461 Hansson. 2021. Four distinct trajectories of tau deposition identified in Alzheimer's disease.
2462 *Nat. Med.* 27:871–881. doi:10.1038/s41591-021-01309-6.

2463 Wadhwani, A.R., A. Affaneh, S. Van Gulden, and J.A. Kessler. 2019. Neuronal apolipoprotein E4
2464 increases cell death and phosphorylated tau release in alzheimer disease. *Ann. Neurol.*
2465 85:726–739. doi:10.1002/ana.25455.

2466 Waheed, Z., J. Choudhary, F.H. Jatala, null Fatimah, A. Noor, I. Zerr, and S. Zafar. 2023. The Role of
2467 Tau Proteoforms in Health and Disease. *Mol. Neurobiol.* 60:5155–5166. doi:10.1007/s12035-
2468 023-03387-8.

2469 Wallin, A.K., K. Blennow, H. Zetterberg, E. Londos, L. Minthon, and O. Hansson. 2010. CSF biomarkers
2470 predict a more malignant outcome in Alzheimer disease. *Neurology*. 74:1531–1537.
2471 doi:10.1212/WNL.0b013e3181dd4dd8.

2472 Wang, C., and D.M. Holtzman. 2020. Bidirectional relationship between sleep and Alzheimer's
disease: role of amyloid, tau, and other factors. *Neuropsychopharmacol. Off. Publ. Am. Coll.*
2473 Neuropsychopharmacol.* 45:104–120. doi:10.1038/s41386-019-0478-5.
2474

2475 Wang, C., R. Najm, Q. Xu, D.-E. Jeong, D. Walker, M.E. Balestra, S.Y. Yoon, H. Yuan, G. Li, Z.A. Miller,
2476 B.L. Miller, M.J. Malloy, and Y. Huang. 2018. Gain of toxic apolipoprotein E4 effects in human
2477 iPSC-derived neurons is ameliorated by a small-molecule structure corrector. *Nat. Med.*
2478 24:647–657. doi:10.1038/s41591-018-0004-z.

2479 Wang, C., A. Nambiar, M.R. Strickland, C. Lee, S. Parhizkar, A.C. Moore, E.S. Musiek, J.D. Ulrich, and
2480 D.M. Holtzman. 2023. APOE-ε4 synergizes with sleep disruption to accelerate Aβ deposition
2481 and Aβ-associated tau seeding and spreading. *J. Clin. Invest.* 133:e169131.
2482 doi:10.1172/JCI169131.

2483 Wang, C., M. Xiong, M. Gratuze, X. Bao, Y. Shi, P.S. Andhey, M. Manis, C. Schroeder, Z. Yin, C.
2484 Madore, O. Butovsky, M. Artyomov, J.D. Ulrich, and D.M. Holtzman. 2021. Selective removal
2485 of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and
2486 decreases synaptic phagocytosis by microglia. *Neuron*. 109:1657-1674.e7.
2487 doi:10.1016/j.neuron.2021.03.024.

2488 Wang, P., and Y. Ye. 2021. Filamentous recombinant human Tau activates primary astrocytes via an
2489 integrin receptor complex. *Nat. Commun.* 12:95. doi:10.1038/s41467-020-20322-w.

2490 Wattmo, C., K. Blennow, and O. Hansson. 2020. Cerebro-spinal fluid biomarker levels:
2491 phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's
2492 disease. *BMC Neurol.* 20:10. doi:10.1186/s12883-019-1591-0.

2493 Wegmann, S., R.E. Bennett, L. Delorme, A.B. Robbins, M. Hu, D. McKenzie, M.J. Kirk, J. Schiantarelli,
2494 N. Tunio, A.C. Amaral, Z. Fan, S. Nicholls, E. Hudry, and B.T. Hyman. 2019. Experimental
2495 evidence for the age dependence of tau protein spread in the brain. *Sci. Adv.* 5:eaaw6404.
2496 doi:10.1126/sciadv.aaw6404.

2497 Wegmann, S., J. Biernat, and E. Mandelkow. 2021. A current view on Tau protein phosphorylation in
2498 Alzheimer's disease. *Curr. Opin. Neurobiol.* 69:131–138. doi:10.1016/j.conb.2021.03.003.
2499 Weigand, A.J., K.R. Thomas, K.J. Bangen, G.M.L. Eglit, L. Delano-Wood, P.E. Gilbert, A.M. Brickman, 2500 M.W. Bondi, and Alzheimer's Disease Neuroimaging Initiative. 2021. APOE interacts with tau 2501 PET to influence memory independently of amyloid PET in older adults without dementia. 2502 *Alzheimers Dement. J. Alzheimers Assoc.* 17:61–69. doi:10.1002/alz.12173.

2503 Wenger, K., A. Viode, C.N. Schlaffner, P. van Zalm, L. Cheng, T. Dellovade, X. Langlois, A. Bannon, R. 2504 Chang, T.R. Connors, D. Oakley, B. Renard, J. Rappsilber, B. Hyman, H. Steen, and J.A. Steen. 2505 2023. Common mouse models of tauopathy reflect early but not late human disease. *Mol. 2506 Neurodegener.* 18:10. doi:10.1186/s13024-023-00601-y.

2507 Whitwell, J.L., J. Graff-Radford, N. Tosakulwong, S.D. Weigand, M. Machulda, M.L. Senjem, C.G. 2508 Schwarz, A.J. Spychalla, D.T. Jones, D.A. Drubach, D.S. Knopman, B.F. Boeve, N. Ertekin- 2509 Taner, R.C. Petersen, V.J. Lowe, C.R. Jack, and K.A. Josephs. 2018. [18 F]AV-1451 clustering of 2510 entorhinal and cortical uptake in Alzheimer's disease. *Ann. Neurol.* 83:248–257. 2511 doi:10.1002/ana.25142.

2512 Williams, T., A.J. Ruiz, A.M. Ruiz, Q. Vo, W. Tsering, G. Xu, K. McFarland, B.I. Giasson, P. Sullivan, D.R. 2513 Borchelt, and P. Chakrabarty. 2022. Impact of APOE genotype on prion-type propagation of 2514 tauopathy. *Acta Neuropathol. Commun.* 10:57. doi:10.1186/s40478-022-01359-y.

2515 Wolters, E.E., R. Ossenkoppele, S.C.J. Verfaillie, E.M. Coomans, T. Timmers, D. Visser, H. Tuncel, 2516 S.S.V. Golla, A.D. Windhorst, R. Boellaard, W.M. van der Flier, C.E. Teunissen, P. Scheltens, 2517 and B.N.M. van Berckel. 2020. Regional [18F]flortaucipir PET is more closely associated with 2518 disease severity than CSF p-tau in Alzheimer's disease. *Eur. J. Nucl. Med. Mol. Imaging.* 2519 47:2866–2878. doi:10.1007/s00259-020-04758-2.

2520 Wong, W. 2020. Economic burden of Alzheimer disease and managed care considerations. *Am. J. 2521 Manag. Care.* 26:S177–S183. doi:10.37765/ajmc.2020.88482.

2522 Wu, J.W., M. Herman, L. Liu, S. Simoes, C.M. Acker, H. Figueroa, J.I. Steinberg, M. Margittai, R. Kayed, 2523 C. Zurzolo, G. Di Paolo, and K.E. Duff. 2013. Small misfolded Tau species are internalized via 2524 bulk endocytosis and anterogradely and retrogradely transported in neurons. *J. Biol. Chem.* 2525 288:1856–1870. doi:10.1074/jbc.M112.394528.

2526 Xiong, M., H. Jiang, J.R. Serrano, E.R. Gonzales, C. Wang, M. Gratuze, R. Hoyle, N. Bien-Ly, A.P. 2527 Silverman, P.M. Sullivan, R.J. Watts, J.D. Ulrich, G.J. Zipfel, and D.M. Holtzman. 2021. APOE 2528 immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving 2529 cerebrovascular function. *Sci. Transl. Med.* 13:eabd7522. doi:10.1126/scitranslmed.abd7522.

2530 Xu, C., D. Xiao, B.B. Su, J.M. Saveron, D. Gamez, R.O. Navia, N. Wang, U. Roy, D.A. Adjeroh, K. Wang, 2531 and Alzheimer and Disease Neuroimaging Initiative. 2024. Association of APOE gene with 2532 longitudinal changes of CSF amyloid beta and tau levels in Alzheimer's disease: racial 2533 differences. *Neurol. Sci. Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol.* 45:1041–1050. 2534 doi:10.1007/s10072-023-07076-1.

2535 Xu, H., T.W. Rösler, T. Carlsson, A. de Andrade, J. Bruch, M. Höllerhage, W.H. Oertel, and G.U. 2536 Höglinger. 2014. Memory deficits correlate with tau and spine pathology in P301S MAPT 2537 transgenic mice. *Neuropathol. Appl. Neurobiol.* 40:833–843. doi:10.1111/nan.12160.

2538 Yamada, K., J.R. Cirrito, F.R. Stewart, H. Jiang, M.B. Finn, B.B. Holmes, L.I. Binder, E.-M. Mandelkow, 2539 M.I. Diamond, V.M.-Y. Lee, and D.M. Holtzman. 2011. In vivo microdialysis reveals age- 2540 dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. 2541 *J. Neurosci. Off. J. Soc. Neurosci.* 31:13110–13117. doi:10.1523/JNEUROSCI.2569-11.2011.
2542 Yamazaki, Y., N. Zhao, T.R. Caulfield, C.-C. Liu, and G. Bu. 2019. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. *Nat. Rev. Neurol.* 15:501–518.
doi:10.1038/s41582-019-0228-7.

2545 Yan, S., C. Zheng, M.D. Paranjpe, Y. Li, W. Li, X. Wang, T.L.S. Benzinger, J. Lu, and Y. Zhou. 2021. Sex modifies APOE ε4 dose effect on brain tau deposition in cognitively impaired individuals. *Brain J. Neurol.* 144:3201–3211. doi:10.1093/brain/awab160.

2548 Yeh, F.L., D. V. Hansen, and M. Sheng. 2017. TREM2, Microglia, and Neurodegenerative Diseases. *Trends Mol. Med.* 23:512–533. doi:10.1016/j.molmed.2017.03.008.

2550 Yeh, F.L., Y. Wang, I. Tom, L.C. Gonzalez, and M. Sheng. 2016. TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ, and Thereby Facilitates Uptake of Amyloid-Beta by Microglia. *Neuron.* 91:328–340. doi:10.1016/j.neuron.2016.06.015.

2553 Yin, Z., N. Rosenzweig, K.L. Kleemann, X. Zhang, W. Brandão, M.A. Margeta, C. Schroeder, K.N. Sivanathan, S. Silveira, C. Gauthier, D. Mallah, K.M. Pitts, A. Durao, S. Herron, H. Shorey, Y. Cheng, J.-L. Barry, R.K. Krishnan, S. Wakelin, J. Rhee, A. Yung, M. Aronchik, C. Wang, N. Jain, X. Bao, E. Gerrits, N. Brouwer, A. Deik, D.G. Tenen, T. Ikezu, N.G. Santander, G.L. McKinsey, C. Baufeld, D. Sheppard, S. Krasemann, R. Nowarski, B.J.L. Eggen, C. Clish, R.E. Tanzi, C. Madore, T.D. Arnold, D.M. Holtzman, and O. Butovsky. 2023. APOE4 impairs the microglial response in Alzheimer's disease by inducing TGFβ-mediated checkpoints. *Nat. Immunol.* 24:1839–1853. doi:10.1038/s41590-023-01627-6.

2561 Yoshiyama, Y., M. Higuchi, B. Zhang, S.-M. Huang, N. Iwata, T.C. Saido, J. Maeda, T. Suhara, J.Q. Trojanowski, and V.M.-Y. Lee. 2007. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. *Neuron.* 53:337–351. doi:10.1016/j.neuron.2007.01.010.

2564 Young, C.B., E.C. Mormino, K.L. Poston, K.A. Johnson, D.M. Rentz, R.A. Sperling, and K.V. Papp. 2023. Computerized cognitive practice effects in relation to amyloid and tau in preclinical Alzheimer's disease: Results from a multi-site cohort. *Alzheimers Dement. Amst. Neth.* 15:e12414. doi:10.1002/dad2.12414.

2568 Yu, J.-T., L. Tan, and J. Hardy. 2014. Apolipoprotein E in Alzheimer's disease: an update. *Annu. Rev. Neurosci.* 37:79–100. doi:10.1146/annurev-neuro-071013-014300.

2570 Zalocusky, K.A., R. Najm, A.L. Taubes, Y. Hao, S.Y. Yoon, N. Koutsodendris, M.R. Nelson, A. Rao, D.A. Bennett, J. Bant, D.-E.J. Amornkul, Q. Xu, A. An, O. Cisne-Thomson, and Y. Huang. 2021. Neuronal ApoE upregulates MHC-I expression to drive selective neurodegeneration in Alzheimer's disease. *Nat. Neurosci.* 24:786–798. doi:10.1038/s41593-021-00851-3.

2574 Zempel, H., E. Thies, E. Mandelkow, and E.-M. Mandelkow. 2010. Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. *J. Neurosci. Off. J. Soc. Neurosci.* 30:11938–11950. doi:10.1523/JNEUROSCI.2357-10.2010.

2578 Zeng, H., J. Huang, H. Zhou, W.J. Meilandt, B. Dejanovic, Y. Zhou, C.J. Bohlen, S.-H. Lee, J. Ren, A. Liu, Z. Tang, H. Sheng, J. Liu, M. Sheng, and X. Wang. 2023. Integrative in situ mapping of single-cell transcriptional states and tissue histopathology in a mouse model of Alzheimer's disease. *Nat. Neurosci.* 26:430–446. doi:10.1038/s41593-022-01251-x.

2582 Zetterberg, H., M.A. Hietala, M. Jonsson, N. Andreasen, E. Styrud, I. Karlsson, A. Edman, C. Popa, A. Rasulzada, L.-O. Wahlund, P.D. Mehta, L. Rosengren, K. Blennow, and A. Wallin. 2006. doi:10.1038/s41582-019-0228-7.
2584 Neurochemical aftermath of amateur boxing. *Arch. Neurol.* 63:1277-1280.
2585 doi:10.1001/archneur.63.9.1277.

2586 Zhang, H., Y. Cao, L. Ma, Y. Wei, and H. Li. 2021a. Possible Mechanisms of Tau Spread and Toxicity in Alzheimer's Disease. *Front. Cell Dev. Biol.* 9:707268. doi:10.3389/fcell.2021.707268.

2588 Zhang, H., W. Wei, M. Zhao, L. Ma, X. Jiang, H. Pei, Y. Cao, and H. Li. 2021b. Interaction between Aβ and Tau in the Pathogenesis of Alzheimer's Disease. *Int. J. Biol. Sci.* 17:2181-2192.
2590 doi:10.7150/ijbs.57078.

2591 Zhang, M.M., R. Bahal, T.P. Rasmussen, J.E. Manautou, and X.-B. Zhong. 2021c. The growth of siRNA-based therapeutics: Updated clinical studies. *Biochem. Pharmacol.* 189:114432.
2592 doi:10.1016/j.bcp.2021.114432.
2593

2594 Zhang, Y., K. Chen, S.A. Sloan, M.L. Bennett, A.R. Scholze, S. O'Keeffe, H.P. Phatnani, P. Guarnieri, C. Caneda, N. Ruderisch, S. Deng, S.A. Liddelow, C. Zhang, R. Daneman, T. Maniatis, B.A. Barres, and J.Q. Wu. 2014. An RNA-Sequencing Transcriptome and Splicing Database of Glia, Neurons, and Vascular Cells of the Cerebral Cortex. *J. Neurosci.* 34:11929-11947.
2597 doi:10.1523/JNEUROSCI.1860-14.2014.
2598

2599 Zhao, J., M.D. Davis, Y.A. Martens, M. Shinohara, N.R. Graff-Radford, S.G. Younkin, Z.K. Wszolek, T. Kanekiyo, and G. Bu. 2017. APOE ε4/ε4 diminishes neurotrophic function of human iPSC-derived astrocytes. *Hum. Mol. Genet.* 26:2690-2700. doi:10.1093/hmg/ddx155.

2602 Zhao, J., Y. Fu, Y. Yamazaki, Y. Ren, M.D. Davis, C.-C. Liu, W. Lu, X. Wang, K. Chen, Y. Cherukuri, L. Jia, Y.A. Martens, L. Job, F. Shue, T.T. Nguyen, S.G. Younkin, N.R. Graff-Radford, Z.K. Wszolek, D.A. Brafman, Y.W. Asmann, N. Ertekin-Taner, T. Kanekiyo, and G. Bu. 2020. APOE4 exacerbates synapse loss and neurodegeneration in Alzheimer's disease patient iPSC-derived cerebral organoids. *Nat. Commun.* 11:5540. doi:10.1038/s41467-020-19264-0.

2607 Zhao, N., C.-C. Liu, W. Qiao, and G. Bu. 2018a. Apolipoprotein E, Receptors, and Modulation of Alzheimer's Disease. *Biol. Psychiatry.* 83:347-357. doi:10.1016/j.biopsych.2017.03.003.

2609 Zhao, N., C.-C. Liu, A.J. Van Ingelgom, C. Linares, A. Kurti, J.A. Knight, M.G. Heckman, N.N. Diehl, M. Shinohara, Y.A. Martens, O.N. Attrebi, L. Petrucelli, J.D. Fryer, Z.K. Wszolek, N.R. Graff-Radford, R.J. Caselli, M.Y. Sanchez-Contreras, R. Rademakers, M.E. Murray, S. Koga, D.W. Dickson, O.A. Ross, and G. Bu. 2018b. APOE ε2 is associated with increased tau pathology in primary tauopathy. *Nat. Commun.* 9:4388. doi:10.1038/s41467-018-06783-0.

2614 Zhou, Y., W.M. Song, P.S. Andhey, A. Swain, T. Levy, K.R. Miller, P.L. Poliani, M. Cominelli, S. Grover, S. Gilfillan, M. Cella, T.K. Ulland, K. Zaitsev, A. Miyashita, T. Ikeuchi, M. Sainouchi, A. Kakita, D.A. Bennett, J.A. Schneider, M.R. Nichols, S.A. Beausoleil, J.D. Ulrich, D.M. Holtzman, M.N. Artyomov, and M. Colonna. 2020. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease. *Nat. Med.* 26:131-142. doi:10.1038/s41591-019-0695-9.

2620 Zhu, B., Y. Liu, S. Hwang, K. Archuleta, H. Huang, A. Campos, R. Murad, J. Piña-Crespo, H. Xu, and T.Y. Huang. 2022. Trem2 deletion enhances tau dispersion and pathology through microglia exosomes. *Mol. Neurodegener.* 17:58. doi:10.1186/s13024-022-00562-8.

2623 Zwang, T.J., E.D. Sastre, N. Wolf, N. Ruiz-Uribe, B. Woost, Z. Hoglund, Z. Fan, J. Bailey, L. Nfor, L. Buée, K.P.R. Nilsson, B.T. Hyman, and R.E. Bennett. 2024. Neurofibrillary tangle-bearing
2625 neurons have reduced risk of cell death in mice with Alzheimer's pathology. *Cell Rep.*

2626 43:114574. doi:10.1016/j CELREP.2024.114574.

2627